Pharmaceutical

HLC-001 by Human Life CORD Japan for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome: Likelihood of Approval

HLC-001 is under clinical development by Human Life CORD Japan and currently in Phase I for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome.

Jan 6, 2025 - 06:00
HLC-001 is under clinical development by Human Life CORD Japan and currently in Phase I for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome.
Read the original article

Tags:

Previous Article

CD19-CD22 CAR-T cells by Shanghai Biomed-Union Biotechnology for Unspecified B-C...

Next Article

GCC-4001 by Artiva Biotherapeutics for Rheumatoid Arthritis: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA grants fast track designation for Verastem’s NSCLC therapy

FDA grants fast track designation for Verastem’s NSCLC ...

Jan 19, 2024

STAT+: Astellas withdraws lawsuit after evading Medicare drug price negotiations

STAT+: Astellas withdraws lawsuit after evading Medicar...

Sep 6, 2023

Myrtelle gets ILAP status from UK for Canavan disease therapy candidate

Myrtelle gets ILAP status from UK for Canavan disease t...

Apr 26, 2023